CHOLANGIOCARCINOMA NON-RESECTABLE
Clinical trials for CHOLANGIOCARCINOMA NON-RESECTABLE explained in plain language.
Never miss a new study
Get alerted when new CHOLANGIOCARCINOMA NON-RESECTABLE trials appear
Sign up with your email to follow new studies for CHOLANGIOCARCINOMA NON-RESECTABLE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug CT-95 targets tough cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called CT-95 in people with advanced cancers that have a protein called mesothelin on their cells. The main goals are to find a safe dose and see if the drug can shrink tumors. About 70 adults with ovarian, lung, pancreatic, or other mesoth…
Matched conditions: CHOLANGIOCARCINOMA NON-RESECTABLE
Phase: PHASE1 • Sponsor: Context Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Triple therapy takes on bile duct cancer: hope for unresectable cases
Disease control Recruiting nowThis phase 2 trial is testing a combination of radiation beads (Y-90), immunotherapy (durvalumab), and chemotherapy (gemcitabine and cisplatin) in 30 people with advanced bile duct cancer that cannot be removed surgically. The goal is to see if this mix can slow cancer growth and…
Matched conditions: CHOLANGIOCARCINOMA NON-RESECTABLE
Phase: PHASE2 • Sponsor: Beth Israel Deaconess Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Liver-targeted chemo shows promise for tough bile duct cancer
Disease control Recruiting nowThis study tests giving chemotherapy drugs (gemcitabine and oxaliplatin) directly into the liver's main artery for people with advanced bile duct cancer that hasn't spread elsewhere. The goal is to shrink tumors while reducing side effects. About 40 adults who have already tried …
Matched conditions: CHOLANGIOCARCINOMA NON-RESECTABLE
Phase: PHASE2 • Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC